Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Daxdilimab - Horizon Therapeutics

Next Previous
X
Search
Drug Profile

Daxdilimab - Horizon Therapeutics

Alternative Names: anti-ILT7 antibody; Daxdilimab - Viela Bio; HZN-7734; MEDI-7734; VIB-7734

Latest Information Update: 05 Mar 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator SBI Biotech
  • Developer Horizon Therapeutics plc; Viela Bio
  • Class Anti-inflammatories; Monoclonal antibodies; Skin disorder therapies; Urologics
  • Mechanism of Action Dendritic cell inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Alopecia areata; Dermatomyositis; Discoid lupus erythematosus; Lupus nephritis; Myositis; Systemic lupus erythematosus
  • No development reported Acute lung injury; Cutaneous lupus erythematosus; Polymyositis; Sjogren's syndrome; Systemic scleroderma

Most Recent Events

  • 25 Jan 2024 Horizon Therapeutics completes a phase II trial in Alopecia areata (In adults, In the elderly) in the US and Canada (SC, Injection) (NCT05368103)
  • 04 Jan 2024 Horizon Therapeutics terminates a phase II trial in Lupus nephritis in the US, Israel, Poland, Serbia, Spain, Argentina, Croatia, Malaysia, Philippines, Brazil, Taiwan and Thailand (SC) due to the sponsor's decision(NCT05540665) (EudraCT2022-001377-31)
  • 15 Dec 2023 Phase-II clinical trials in Dermatomyositis (Treatment-experienced) in Australia, Czech Republic, Italy, Mexico, Spain, Spain, United Kingdom (SC) (NCT05669014)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top